ArticleJournal of ophthalmology2022
Real-World Cataract Surgery Complications and Secondary Interventions Incidence Rates: An Analysis of US Medicare Claims Database.
Article in Journal of ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 13 citations in OpenAlex.
- Rates and associated risk factors for cataract surgery complications in academic medical centers.Journal of cataract and refractive surgery · 2026Article
- Lens epithelial cells senescence in cataract pathogenesis and emerging therapeutic opportunities.Frontiers in cell and developmental biology · 2026Review
- Comparative analysis of cataract surgery outcomes in elderly Jewish and Arab patients from Northern Israel, a retrospective cohort study.Frontiers in ophthalmology · 2026Article
- Predictive Utility of Epic's Health Composite Score for Same-Day Cancellation in Cataract Surgery.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- The Efficacy and Safety of Nanoparticle-Based Clobetasol Propionate in Managing the Inflammation and Pain in Post-Operative Cataract Patients: A Systematic Review and Meta-Analysis.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- From Routine to Risk: Medical Liability and the Legal Implications of Cataract Surgery in the Age of Trivialization.Journal of clinical medicine · 2025Review
- Posterior capsule opacification treatment using Nd: YAG laser capsulotomy: 36 months retrospective analysis.BMC ophthalmology · 2025Article
- Innovative Polymeric Biomaterials for Intraocular Lenses in Cataract Surgery.Journal of functional biomaterials · 2024Review
- Efficacy and safety of the implantation of a single-piece angulated foldable IOL in the sulcus.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024Article
- PhacoTrainer: Deep Learning for Cataract Surgical Videos to Track Surgical Tools.Translational vision science & technology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To characterize cataract patients and postoperative outcomes in the Medicare fee-for-service (FFS) population. Design: A retrospective observational cohort study. Methods: Medicare fee-for-service (A&B) databases were queried from October 2015 to December 2017. Patients with procedural claims using CPT codes (66982 or 66984) and with 1-12 months of postcataract follow-up data were included in the analysis. Results: 133,896 records of 82,246 CMS FFS claims were included in the analysis. The average patient age was 73.8, and 58.2% were females. The cataract surgery setting was ASC (71.3%) followed by HOPD (27.6%). The median time between first and second surgery was 15 days. The most common comorbidities included diabetes (28.6%), glaucoma (22.1%), and macular degeneration (21.7%). Posterior capsule rupture occurred in 0.2% of cases. The <6 months cumulative incidence of most common secondary surgical interventions was 4.7%, 0.2%, and 0.2% for Nd:YAG capsulotomy, IOL exchange, and IOL repositioning, respectively.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.